 Wells Fargo reiterated its Overweight rating and raised its price target to 17 from 13 for Kezar Life Sciences Inc NASDAQ: KZR on zetomipzomibs zeto positive Ph2 MISSION data in lupus nephritis LN. The analysts say that the data is in-line with. 